CDK7 and glioblastoma: The anti-cancer effect of the covalent CDK7 inhibitor has been demonstrated in a variety of tumors, including leukemia (Zhou et al., 2021), bladder cancer (Liu et al., 2022), glioblastoma (Meng et al., 2018), oesophageal squamous cell carcinoma (Hu et al., 2019), and osteosarcoma (Taniue and Akimitsu, 2022).